Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRRO 
Frequency Therapeutics Inc (KRRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: KRRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $43.25
1 Year Target Price $43.25
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.52% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.66M USD | Price to earnings Ratio - | 1Y Target Price 43.25 |
Price to earnings Ratio - | 1Y Target Price 43.25 | ||
Volume (30-day avg) 10 | Beta 2.21 | 52 Weeks Range 5.20 - 55.89 | Updated Date 12/2/2025 |
52 Weeks Range 5.20 - 55.89 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.42 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -2.6775 | Actual -1.92 |
Profitability
Profit Margin - | Operating Margin (TTM) -1764.86% |
Management Effectiveness
Return on Assets (TTM) -29.16% | Return on Equity (TTM) -63.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5867581 | Price to Sales(TTM) 6.87 |
Enterprise Value 5867581 | Price to Sales(TTM) 6.87 | ||
Enterprise Value to Revenue 0.8 | Enterprise Value to EBITDA -5.6 | Shares Outstanding 9417295 | Shares Floating 5778546 |
Shares Outstanding 9417295 | Shares Floating 5778546 | ||
Percent Insiders 6.16 | Percent Institutions 104.05 |
Upturn AI SWOT
Frequency Therapeutics Inc
Company Overview
History and Background
Frequency Therapeutics, Inc. was founded in 2014. It is a biotechnology company focused on developing disease-modifying therapeutics for hearing loss based on its Progenitor Cell Activation (PCA) platform.
Core Business Areas
- Hearing Restoration: Focused on developing therapeutics to restore hearing function through the regeneration of hair cells within the inner ear.
Leadership and Structure
David Lucchino is the CEO. The company has a board of directors and various functional departments including research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- FX-322: FX-322 is Frequency Therapeutics' lead product candidate. It is designed to regenerate hair cells in the inner ear to treat sensorineural hearing loss. As of late 2023, it has not yet reached market. Competitors include pharmaceutical companies and research institutions working on gene therapy, stem cell therapy, and other drug-based approaches for hearing loss.
Market Dynamics
Industry Overview
The hearing loss therapeutics market is large and underserved, with a growing aging population and increasing noise exposure contributing to its expansion. The market currently relies on hearing aids and cochlear implants, with limited options to restore hearing
Positioning
Frequency Therapeutics aims to disrupt the hearing loss market by developing a disease-modifying therapy that restores hearing. Their PCA platform differentiates them from companies focused on symptomatic treatments. Clinical trials of FX-322 have presented mixed results.
Total Addressable Market (TAM)
The total addressable market for hearing loss therapeutics is estimated to be billions of dollars. Frequency Therapeutics, with its regenerative approach, aims to capture a significant portion of this market if FX-322 or other PCA-based therapies are approved and commercialized.
Upturn SWOT Analysis
Strengths
- Proprietary PCA technology platform
- Potential to address a large unmet medical need
- Experienced management team
Weaknesses
- FX-322 clinical trial results have been mixed and haven't achieved statistical significance in pivotal trails
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on a single lead product candidate
Opportunities
- Potential for strategic partnerships with larger pharmaceutical companies
- Expansion of PCA platform to other disease areas
- Positive clinical trial results for FX-322 or other PCA-based therapies
Threats
- Failure to obtain regulatory approval for FX-322
- Competition from other companies developing hearing loss therapies
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- LLY
- SANA
- DTIL
Competitive Landscape
Frequency Therapeutics faces significant competition from established pharmaceutical companies and emerging biotechnology firms developing hearing loss therapies. Competitors employ various approaches, including gene therapy, stem cell therapy, and small molecule drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been very limited as Frequency Therapeutics focuses on research and development.
Future Projections: Future growth projections depend on the successful development and commercialization of FX-322 or other PCA-based therapies. Analyst estimates are highly speculative and contingent on clinical trial outcomes.
Recent Initiatives: Recent initiatives include ongoing clinical trials of FX-322, and efforts to secure funding.
Summary
Frequency Therapeutics is a high-risk, high-reward biotechnology company focused on developing a novel treatment for hearing loss. While their PCA technology has the potential to revolutionize the market, the company faces challenges with its clinical trial results, limited financial resources, and intense competition. Positive clinical trial outcomes are critical for the company's success. Investors should be aware of the significant risks involved.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Various Market Data Sources
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Frequency Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2023-11-06 | CEO, President, Interim CFO, Principal Financial Officer & Director Dr. Ram Aiyar MBA, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 87 | Website https://www.korrobio.com |
Full time employees 87 | Website https://www.korrobio.com | ||
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.